Central Nervous System
Controlepsy
Lamotrigine 100 mg - 30 Tablets
Lamotrigine 50 mg - 30 Tablets
Lamotrigine 25 mg - 30 Tablets
Composition:
Controlepsy 25 mg: Each tablet contains 25 mg lamotrigine.
Excipients with known effect: Lactose: 34.50 mg.
Controlepsy 50 mg: Each tablet contains 50 mg lamotrigine.
Excipients with known effect: Lactose: 69.00 mg.
Controlepsy 100 mg: Each tablet contains 100 mg lamotrigine.
Excipients with known effect: Lactose: 138 mg.
Therapeutic Indications:
Epilepsy:
Adults and adolescents aged 13 years and above:
Adjunctive or monotherapy treatment of partial seizures and generalized seizures, including tonic-clonic seizures.
Seizures associated with Lennox-Gastaut syndrome.
Controlepsy is given as an adjunctive therapy but may be the initial antiepileptic drug (AED) to start with in Lennox-Gastaut syndrome.
Children and adolescents aged 2 to 12 years:
Adjunctive treatment of partial seizures and generalized seizures, including tonic-clonic seizures and the seizures associated with Lennox-Gastaut syndrome.
Monotherapy of typical absence seizures.
Bipolar disorder:
Adults aged 18 years and above:
Prevention of depressive episodes in patients with bipolar I disorder who experience predominantly depressive episodes.
Controlepsy is not indicated for the acute treatment of manic or depressive episodes.
Approved by Egyptian Drug Authority: HF0294OA4548/102025 . Invalidation date: 20/10/2026
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at www.edaegypt.gov.eg”